Pfizer Submits Covid Shot for Kids Under 5 for FDA Clearance (1)

June 1, 2022, 10:23 PM UTC

Pfizer Inc. asked U.S. regulators to clear its Covid-19 vaccine for emergency use in children under age 5, an effort to extend protection against the virus to the country’s youngest.

The drugmaker and BioNTech SE finalized their rolling application to the Food and Drug Administration for emergency-use authorization of their vaccine in kids ages 6 months through 4 years old, the companies said in a statement on Wednesday. The vaccine partners began the submission process in February.

Pfizer and BioNTech announced in late May that a three-shot regimen was highly effective and prompted a strong immune response in children under ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.